Yeah notice thr rah rah rah here has died down since the sp has settled down. Not really sure what to think if we get some good results from the colon cancer trial in Leeds. Under the circumstance of good results I think it would require the company to come out with some aggressive plans for any indication related to that in the EU. I haven't bought options for a long time because of potential dead times like this. Also, some have speculated here that a SC denial for the writ would spur Hikma into possibly seeking a settlement but that does Amsrin no good. They need to invalidate the patent in order to rid us of all the GVs.
Market Data 
Markets 
AI
